entertainment -WSS

entertainment

author：hotspot 2025-08-23 05:01:11 - browse：89618

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： BIO to announce reorganization, senior leaders expected to depart

WSS

Oak Street deal isn't the answer to health care's woes

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Can gargling with Listerine treat gonorrhea of the mouth?

The United States must get value

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Lilly’s weekly insulin works as well as daily products, new studies show

hotspot

entertainment

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Primary care doctor shortage won't be solved by free med school tuition

DIEP, the 'gold standard' of breast reconstruction, is under threat

Welsh Carson private equity firm escapes from FTC antitrust case

Virginia high school admissions case could be legal follow

Free medical tuition alone isn't enough to close gaps in primary care

DIEP, the 'gold standard' of breast reconstruction, is under threat

Class action alleges UnitedHealth concealed DOJ probe

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Deliver public health messages at the right time

Wikipedia

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Obesity drug from Roche shows promise in early study

STAT series 'Denied by AI' wins major journalism prizes

HHS's proposed rule does nothing to address the climate crisis

As health system earnings go up, health insurance stocks go down

Novo Nordisk testing Wegovy against alcohol

hotspot

entertainment

entertainment

explore